ROPLASS supplies MSDBD (Multi-hollow Surface Dielectric Barrier Discharge) plasma technology that generates plasma-activated ozone- and hydrogen-peroxide-rich atmospheres — enabling low-temperature decontamination of bacteria, biofilms and spores on thermally sensitive medical devices, biomaterials and pharmaceutical packaging without direct plasma exposure to the treated items. The same DCSBD platform is also used by biomedical-materials researchers to functionalise polymer surfaces for non-fouling coatings, wound-dressing nanofibers and drug-delivery vehicles.
Unlike autoclave sterilisation (heat), ethylene-oxide (toxic residues) or hydrogen-peroxide vapour (requires expensive delivery equipment), ROPLASS MSDBD generates the biocidal chemistry — ozone plus H₂O₂ from ambient humidity — inside the treatment chamber itself, on demand, from air and water only. The result: a compact, room-temperature, residue-free biodecontamination cycle validated on antibiotic-resistant bacteria, biofilms and bacterial spores.
How MSDBD generates ozone and H₂O₂ from ambient air and water — for indirect decontamination
The Multi-hollow Surface Dielectric Barrier Discharge (MSDBD) is a novel plasma source developed at CEPLANT (Masaryk University) and commercialised by ROPLASS. Instead of exposing the treated item directly to the plasma, MSDBD is used to activate the gas atmosphere (air, N₂, O₂ or humid air) that fills the sealed chamber — producing high concentrations of ozone (O₃) and hydrogen peroxide (H₂O₂) that then diffuse to the item and inactivate microorganisms indirectly. The efficiency of ozone production in this configuration was quantified in [Homola et al., Plasma Chemistry and Plasma Processing 39(5), 2019] and the MSDBD unit itself was characterised as an ozone generator of supreme efficiency in [Homola et al., Plasma Sources Science and Technology 29(9), 2020 — 75 citations].
The MSDBD principle also enables nitrogen fixation via aerosol delivery [Fujera et al., Plasma Sources Science and Technology 33(7), 2024] and creates the technical foundation for the RPS30+ biodeco product — a dedicated biodecontamination chamber that inactivates bacterial biofilms, spores and antibiotic-resistant strains without direct plasma exposure [Kelar Tučeková et al., Molecules 26(4), 2021].
How DCSBD atmospheric plasma prepares polymer surfaces for medical-grade non-fouling coatings
Beyond direct decontamination, ROPLASS plasma is used to functionalise polymer surfaces for biomedical applications where fouling by proteins, cells or biofilms is a critical failure mode. Cold atmospheric plasma treatment of polymer substrates enables the deposition of non-fouling poly(2-oxazoline)-based coatings for implantable and diagnostic devices [Šrámková et al., Scientific Reports 10, 2020], hydrophobic photocatalytic self-cleaning surfaces based on hydroxyapatite and TiO₂ multilayers [Kaindl et al., Surface and Coatings Technology 511, 2025], and electron-beam-produced non-biofouling hydrogel layers on multiple substrates [Šrámková et al., Applied Surface Science 625, 2023].
The same platform is used to modify silicon-polyurethane sol-gel coatings for medical applications [Chwatal et al., New Journal of Chemistry 48(12), 2024]. All processes operate at low temperature and in ambient air, without noble-gas consumables or wet-chemical grafting steps.
DCSBD-treated nanofibers, electrospun scaffolds and drug-delivery nanostructures for medical research
ROPLASS plasma technology supports biomedical materials research across wound dressings, cell culture scaffolds and drug delivery systems. Applications include plasma-treated electrospun polycaprolactone / gelatin nanofibers with halloysite for wound healing [Pavliňáková et al., Materials Science and Engineering C 91, 2018], antibacterial pre-treatment of nonwoven fabrics for the deposition of poly(l-lactide) nanoparticles [Ivanova et al., Plasma Processes and Polymers 14(10), 2017], and Cisplatin-crosslinked DNA origami nanostructures for targeted drug delivery [Sala et al., ACS Applied Nano Materials 5(9), 2022].
For therapeutic applications, ROPLASS plasma has been used in combination with radiation for a novel approach to cervical cancer (HeLa) cell studies [Jamaati Kenari et al., Bioorganic Chemistry 111, 2021], and for pathogen inactivation in recirculation aquaculture systems and drinking-water disinfection [Villar-Navarro et al., Solar Energy 227, 2021]. Recent work extends the platform to rapid electrochemical activation of 3D-printed carbon electrodes for pharmaceutical drug analysis [Kováč et al., ACS Omega 10(35), 2025].
Related products
RPS30+ biodeco (specialty work)
dedicated biodecontamination chamber implementing the MSDBD principle described on this page
RPS30 multi-hollow (bench)
for laboratory research on plasma-activated ozone / H₂O₂ chemistry